ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1632642
This article is part of the Research TopicAntibody-Mediated Thrombotic DiseaseView all 4 articles
IMPACT OF ANTIPHOSPHOLIPID AND ANTINUCLEAR ANTIBODIES IN CORONARY ARTERY DISEASE PROGRESSION
Provisionally accepted
Tamara García Camarero1,2*
Víctor Manuel Martínez-Taboada2
Juan Irure-Ventura2
Jose M De La Torre Hernandez2
Comins-Boo Alejandra2
Marcos Lopez-Hoyos2
Jose Luis Hernández Hernández2- 1Marqués de Valdecilla University Hospital, Santander, Spain
- 2Marqués de Valdecilla Health Research Institute (IDIVAL), Santander, Cantabria, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background/Objectives: The role of antiphospholipid (aPL) and antinuclear antibodies (ANA) in the progression of coronary artery disease (CAD) remains uncertain. We aimed to determine whether the presence of aPL or ANA predicts CAD progression. Methods: We conducted a retrospective, single-center, case-control study including patients with CAD classified as either rapid clinical progressors (RCP) or long-standing stable (LSS), and a population-based control group. Autoantibodies analyzed included anticardiolipin (aCL), anti-β2 glycoprotein I (aB2GPI), anti-phosphatidylserine/prothrombin (anti-PS/PT), and ANA. Results:We included 180 CAD patients (58 RCP, 122 LSS) and 210 matched controls. CAD patients more frequently exhibited positive aCL (p<0.05), whereas aB2GPI IgA was higher among controls. The only significant difference between RCP and LSS was an increased prevalence of aCL IgA in RCP (p<0.05). No consistent differences were found in ANA positivity, antibody subtypes, or overall autoantibody load between groups. Conclusions: This study does not support a significant role for aPL or ANA in the development or progression of CAD. These findings should be interpreted as hypothesis-generating, and larger, prospective multicenter studies with repeated antibody measurements are required to clarify these associations.
Keywords: Coronary Artery Disease, Myocardial Infarction, Antiphospholipid Syndrome, Antiphospholipid antibodies, Antinuclear Antibodies
Received: 21 May 2025; Accepted: 29 Sep 2025.
Copyright: © 2025 García Camarero, Martínez-Taboada, Irure-Ventura, De La Torre Hernandez, Alejandra, Lopez-Hoyos and Hernández Hernández. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tamara García Camarero, tgcamarero@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.